470668-70-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Benzaldehyde, 5-bromo-3-fluoro-2-methoxyserves as a crucial building block in the synthesis of a wide range of pharmaceuticals and agrochemicals. Its unique structure allows it to be a key component in the development of new drugs and agricultural products, enhancing their effectiveness and targeting specific biological pathways.
Used in Flavoring and Fragrance Industries:
Leveraging its pleasant almond-like odor, Benzaldehyde, 5-bromo-3-fluoro-2-methoxyis utilized in the production of flavoring agents and fragrances. It contributes to the creation of various scents and tastes in products such as food, beverages, cosmetics, and perfumes, adding depth and complexity to their sensory profiles.
Used in Research and Development:
Benzaldehyde, 5-bromo-3-fluoro-2-methoxyalso holds potential in research and development as a versatile intermediate for the creation of diverse chemical compounds. Its unique structure and properties make it an attractive candidate for further exploration and innovation, paving the way for new discoveries and applications across various scientific fields.

Upstream product

• 394-50-3 3-fluorosalicylaldehyde 
• 251300-28-4 5-bromo-3-fluoro-2-hydroxybenzaldehyde 
• 74-88-4 methyl iodide 

Downstream Products

• 470668-69-0 5-bromo-3-fluoro-2-methoxybenzyl alcohol 

Relevant academic research and scientific papers

Design and synthesis of novel meta-linked phenylglycine macrocyclic FVIIa inhibitors

Two novel series of meta-linked phenylglycine-based macrocyclic FVIIa inhibitors have been designed to improve the rodent metabolic stability and PK observed with the precursor para-linked phenylglycine macrocycles. Through iterative structure-based design and optimization, the TF/ FVIIa Ki was improved to subnanomolar levels with good clotting activity, metabolic stability, and permeability.

Boron Containing PDE4 Inhibitors

The present invention relates to boron containing compounds of Formula (I) [in-line-formulae]X—Y—Z?? Formula (I)[/in-line-formulae] that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

MACROCYCLIC FACTOR VIIA INHIBITORS

The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.

PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST

The present invention relates to a compounds represented by the formula. The compounds of the present invention have a superior tachykinin receptor antagonistic action, particularly a substance P receptor antagonistic action, and is useful as pharmaceutical agents, for example, tachykinin receptor antagonists, agents for the prophylaxis or treatment of lower urinary tract symptoms, gastrointestinal diseases or central nerve diseases.

BENZENE COMPOUND AND SALT THEREOF

The present invention provides a medicament comprising a benzene compound useful as an insulin sensitizer, a salt thereof or a hydrate of them and a derivative of them as the active ingredient. Specifically, it provides a benzene compound represented by t